1464results about "Nitrile/isonitrile active ingredients" patented technology

The present invention is directed to the compounds of Formula (IV) inhibitors of KRAS(G12D). The inhibitors described herein can be useful in the treatment of diseases or disorders associated with KRAS(G12D), such as Lung cancer, Pancreatic cancer, Colorectal cancer et al. In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting KRAS(G12D), methods of treating diseases or disorders associated with KRAS(G12D), and methods of synthesizing these compounds.

The invention provides methods and means for the inhibition or neutralisation of death receptor / death ligand members of the tumour necrosis factor superfamil and TNF receptor superfamilies and / or the Toll-like receptor family, and / or NOD-like receptor and / or of the signalling induced via these receptors, preferably in combination with each other and / or with anti-inflammatory agents, in treating diseases such as Acute Respiratory Distress Syndrome (ARDS), such as that caused by airway-targeting viruses, such as SARS coronaviruses.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

To provide a formulation for treating at least one of hypertension, pulmonary hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of the formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion and a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective to injure or damage tissues, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: None

The invention provides combination therapies comprising TNF inhibitor compounds and mitochondrial complex I modulator (MCIM) compounds, which find utility in the medical field of inflammatory and progressive disorders such as RA, IBD, idiopathic pulmonary fibrosis, interstitial lung disease, and MS.

Hydrogen-bonded framework nanoparticles comprising a chemiluminescent compound (e.g., L-012) are provided and can be used, e.g., for sono-optogenetic treatment of neurodegenerative diseases such as Parkinson's disease. Related in vivo and therapeutic methods are also provided.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

The invention provides combination therapies comprising disease modifying anti-rheumatic drugs and mitochondrial complex I modulator (MCIM) compounds, which find utility in the medical field of inflammatory and progressive disorders, for example autoimmune diseases such as arthritis.

The invention discloses an N-phenylbenzenesulfonamide compound as well as a preparation method and application thereof. The compound disclosed by the invention is shown as a formula (I). The compound is an LDHA enzyme inhibitor, is a sulfonamide compound with anti-tumor activity, shows good anti-tumor activity at the cellular level, has good safety and can be used for preparing anti-tumor drugs. # imgabs0 #

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

The present invention relates to methods and compositions for treating hair loss or excessive hair shedding in a subject or for promoting hair growth in a subject. The present invention also relates to an orodispersible composition or a nasally administered composition for treating hair loss or excessive hair shedding in a subject or for promoting hair growth in a subject.

The present disclosure is directed to methods of treating a steatosis-associated disorder and methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and / or conditions associated with a PRKAG2 mutation, by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. Methods of treating a cytoplasmic glycogen storage disorder by administering a lysosomal enzyme and a second therapeutic agent are also described. Other embodiments are directed to methods of treating a cytoplasmic glycogen storage disorder by administering a therapeutic agent as an adjunctive therapy to lysosomal enzyme replacement therapy.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Provided herein are compounds of formula (I), or pharmaceutically acceptable salts or deuterated forms thereof, wherein ring R1, R2, and L are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

The invention provides a marine biological alkali compound. The chemical formula of the marine biological alkali compound is as follows: # imgabs0. The marine biological alkali compound or pharmaceutically acceptable salt thereof can be used for preparing antibacterial drugs or anti-infective drugs. The invention also provides a separation and extraction preparation method or a chemical synthesis preparation method of the marine alkaloid compound or the pharmaceutically acceptable salt thereof, and the preparation method is simple and easy to industrialize. The invention also provides application of the marine biological alkali compound or the pharmaceutically acceptable salt thereof in preparation of antibacterial drugs or anti-infection drugs for human or fish.

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

The invention relates to the field of biological medicine, and provides an application of a dihydroorotate dehydrogenase inhibitor in preparation of megakaryocytes, and the dihydroorotate dehydrogenase inhibitor is a compound shown as a formula I, a formula II or a formula III, or a pharmaceutically acceptable salt of the compound. According to the technical scheme, the dihydroorotate dehydrogenase inhibitor can promote hematopoietic stem / progenitor cells to differentiate into megakaryocytes and platelets, the platelet generation amount is increased by about 2 times, and a promising strategy is provided for in-vivo and in-vitro megakaryocyte and platelet generation.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

The present application relates to compounds of formula (I), and their pharmaceutical compositions / preparations. This application further relates to methods of treating Rett syndrome and / or one or more symptoms associated with Rett syndrome, FOXG1 syndrome and / or one or more symptoms associated with FOXG1 syndrome, CDKL5 deficiency disorder (CDD) and / or one or more symptoms associated with CDD, or CHD8-related neurodevelopmental disorder (CHD8-NDD) and / or one or more symptoms associated with CHD8-NDD, chronic heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), or heart failure with mid-range ejection fraction (HFmrEF).

Disclosed herein are broad-spectrum Coronavirus entry inhibitor compounds and methods of use thereof. Methods disclosed herein include inhibiting Coronavirus infection, treating a Coronavirus infection, and treating a subject at risk of contracting a Coronavirus infection. The compounds described herein target entry of Coronaviruses downstream of binding of the viral receptor.

This invention provides compounds for the inhibition of papain-like proteases (PLpros) for the inhibition of viruses, including compounds of formula (I″), and pharmaceutically acceptable salts thereof.

The invention belongs to the technical field of veterinary drugs, and particularly relates to a 2, 3-disubstituted naphthoquinone compound as well as application and a preparation method thereof, the general formula of the 2, 3-disubstituted naphthoquinone compound is # imgabs0 #, and X is selected from C, NH, O and S; wherein when X is selected from C, an X-R1 substituent is represented as an aryl substituent; when X is selected from NH, R1 is selected from a hydrogen atom, C1-6 alkyl, C3-6 cycloalkyl, substituted aryl, substituted benzyl and substituted acyl; when X is selected from O, R1 is selected from a hydrogen atom, C1-6 alkyl, C3-6 cycloalkyl, substituted benzyl and substituted acyl; when X is selected from S, R1 is selected from C1-6 alkyl, substituted aryl and substituted benzyl; r2 is selected from C1-16 alkyl, substituted aryl, Ra-(CH2) n-, and Ra-CO-(CH2) n-; the series of compounds are novel in structure and good in antibody ectoparasite activity, are successfully applied to the field of veterinary drugs, and solve the long-standing problems of safety and toxicity; the synthesis process is simple, the conditions are mild, and various 2, 3-disubstituted naphthoquinone compounds can be efficiently prepared.

A method for treating prostate cancer by administering a first dose of a polyamine inhibitor for a first interval at a beginning of a first treatment cycle; a second dose of the polyamine inhibitor in combination with a dose of an androgen, or a derivative thereof, at a second interval during the first treatment cycle; and a dose of an antiandrogen at a third interval during the first treatment cycle is disclosed.

The invention provides a preparation method and application of a suspension containing a PDE-4 or PDE-3 / 4 inhibitor for sterile inhalation. The preparation method comprises the following steps: dispersing a PDE-4 or PDE-3 / 4 inhibitor in injection water containing an excipient, and carrying out high-pressure moist heat sterilization to obtain a PDE-4 or PDE-3 / 4 inhibitor dispersion liquid; dissolving the long-acting beta2-receptor stimulant and / or the long-acting muscarinic receptor antagonist, sterilizing and filtering to obtain a mixed solution; and mixing the PDE-4 or PDE-3 / 4 inhibitor dispersion liquid with the mixed solution, dispersing, and carrying out sterile filling. The medicinal preparation prepared by the invention is a sterile inhalation suspension, and the sterile inhalation suspension containing the PDE-4 or PDE-3 / 4 inhibitor is high in bioavailability, good in patient medication compliance and good in preparation stability.

The present invention generally relates to the treatment of Parkinson's disease (PD) in humans. More particularly, it relates to nicotinamide riboside (NR) for use in a method for treatment of Parkinson's disease in a human subject characterized by a particular dosage regimen; pharmaceutical compositions; and dosage forms, which can be for use in or as treatment of Parkinson's disease.

This invention belongs to the field of veterinary drug technology, specifically relating to a 2,3-disubstituted naphthoquinone compound, its uses, and a preparation method. The 2,3-disubstituted naphthoquinone compound has the general formula: where X is selected from C, NH, O, and S; where X is selected from C, the X-R1 substituent represents an aryl substituent; when X is selected from NH, R1 is selected from hydrogen atom, C1-6 alkyl, C3-6 cycloalkyl, substituted aryl, substituted benzyl, or substituted acyl; when X is selected from O, R1 is selected from hydrogen atom, C1-6 alkyl, C3-6 cycloalkyl, C4-6 cycloalkyl, C5-6 cycloalkyl, C6-6 cyclo ... 3-6 cycloalkyl, substituted benzyl, substituted acyl; when X is selected from S, R1 is selected from C1-6 alkyl, substituted aryl, substituted benzyl; R2 is selected from C1-16 alkyl, substituted aryl, Ra-(CH2)n-, Ra-CO-(CH2)n-; This series of compounds has novel structures, excellent antiparasitic activity, and has been successfully applied in the field of veterinary drugs, solving long-standing safety and toxicity problems; its synthesis process is simple, the conditions are mild, and it can efficiently prepare a variety of 2,3-disubstituted naphthoquinone compounds.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Compositions and methods for treating a subject for coronavirus infection are provided. The methods typically involve administering an effective amount of probenecid, its metabolite or analog, or a pharmaceutically acceptable salt thereof to the subject. The methods can be therapeutic and / or prophylactic. The amount of probenecid, its metabolite or analog, or a pharmaceutically acceptable salt thereof can be effective, for example, to reduce viral replication, alleviate one or more symptoms of a virus-related disease, disorder, or illness, or a combination thereof. In a preferred embodiment, the virus is a severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.